1. Kwon-Chung KJ, Edman JC, Wickes BL. Genetic
association of mating types and virulence in
Cryptococcus neoformans. Infect Immun 1992; 60: 602-
605.
2. Kwon-Chung KJ. Cryptococcosis. In: Kwon-Chung KJ,
Bennett JE, eds. Medical Mycology. Philadelphia: Lea
and Febiger, 1992; 397-446.
3. Kwon-Chung KJ, Yun C, Wickes B. The relationship
between mating type and virulence in Cryptococcus
neoformans. 4th International Conference on
Cryptococcus and Cryptococcosis (September 12th-16th
1999) London 1999; 30.
4. Cox GM, Perfect JR. Cryptococcus neoformans
var.neoformans and gattii and Trichosporon species. In:
Coklier L, Balows A, Sussman M. Topley and Wilsons
Microbiology and Microbial Infections. 9th ed. vol 4
Ajello L, Hay RJ vol eds.Medical Mycology 2000; 461-
486.
5. Yücel A. Kriptokok ve Diğer Maya formundaki
mantarlar. İnfeksiyon Hastalõklarnda. 2nci baskõ.
Ed.Wilke A, Söyletir G, Doğanay M. 2001 (Baskõda).
6. Cleare W, Brandt ME, Casadevall A. Monoclonal
antibody 13F1 produces annular fluorescens patterns on
Cryptococcus neoformans serotype AD isolates. J Clin
Microbiol 1999; 37: 3080.
7. Franzot SP, Salkin IF, Casadeval A. Cryptococcus
neoformans var.grubii separate varietal status for
Cryptococcus neoformans serotype A isolates. J Clin
Microbiol 1999; 37: 838-840.
8. Lazera MS, Pires FDA, Camillo-Coura L, Nishikawa
MM, Bezerra CCF, Trilles L, Wanke B. Natural habitat
of Cryptococcus neoformans var.gattii in decaying wood
horming hallows in Işving threes. J Vet Med Mycol 1996;
34: 127-131.
9. Lazera MS. Possible primary echological niche of
Cryptococcus neoformans. 4th International Conference
on Cryptococcus and Cryptococcosis (September 12th-
16th 1999) London 1999; 88.
10. Halliday C, Krockenberger M, Carter D. An investigation
of mating type in Australian isolates of Cryptococcus
neoformans var.gattii using molecular techniques. 4th
International Conference on Cryptococcus and
Cryptococcosis (September 12th-16th 1999) London 1999;
133.
11. Mitchell TG, Perfect JR. Cryptococcosis in the era of
AIDS-100 years after the discovery of Cryptococcus
neoformans. Clin Microbiol Rev 1995; 8: 515-548.
12. Perfect JR, Wong B, Chang YC, Kwon-Chung KJ,
Williamson PR. Cryptococcus neoformans : virulence
and host defences. Med Mycol 1998; 36 (Suppl 1): 79-86.
13. Levitz SM, Dupont MP, Smail EH. Direct activity of
human T lymphocytes and natural killer cells against
Cryptococcus neoformans. Infect Immun 1994; 62: 194-
202.
14. Diamond RD. Cryptococcus neoformans. In: Mandel GL,
Bennett JE, Dolin R, eds. Principles and Practice of
Infectious Diseases. New York: Churchill Livingstone,
1995; 2331-2340.
15. Kozel TR. Virulence factors of Cryptococcus
neoformans. Trends Microbiol 1995; 3: 295-299.
16. Fries BC, Casadevall A. Serial isolates of Cryptococcus
neoformans from patients with AIDS differ in virulence
for mice. J Infect Dis 1998; 178: 1761-1766.
17. Abadi J, Nachatan S, Kressel AB, Pirofski L.
Cryptococcosis in children with AIDS. Clin Infect Dis
1999; 28: 309-313.
18. Agrawal A, Brown WS, McKenzie S. Cryptococcal
arthritis in an immunocompetent host. JSC Med Assoc
2000; 96: 297-299.
CERRAHPAŞA TIP DERGİSİ Cilt (Sayõ) 34 (1)
50
19. Nunez M, Peacock JE Jr, Chin R Jr. Pulmonary
cryptococcosis in the immunocompetent host. Therapy
with oral fluconazole: a report of four cases and a review
of the literature. Chest 2000; 118: 527-534.
20. Prendiville S, Bielamowicz SA, Hawrych A, Deeb ZE.
Isolated cryptococcal sphenoid sinusitis with septicemia,
meningitis, and subsequent skull base osteomyelitis in an
immunocompetent patient. Otolaryngol Head Neck Surg
2000; 123: 277-279.
21. Patel P, Ramanathan J, Kayser M, Baran J Jr. Primary
cutaneous cryptococcosis of the nose in an
immunocompetent woman. J Am Acad Dermatol 2000;
43: 344-345.
22. Buchanan KL. What makes Cryptococcus neoformans a
pathogen? Emerging Infect Dis 1998; 4: 16-22.
23. Kwon-Chung KJ, Bennett JE. Distribution of and mating
types of Cryptococcus neoformans among natural and
clinical isolates. Am J Epidemiol 1978; 108: 337-340.
24. Hamilton AJ, Goodley J. Virulence factors of
Cryptococcus neoformans. Curr Top Med Mycol 1996;
19-42.
25. Dong ZM, Murphy JW. Mobility of human neutrophils in
responce to Cryptococcus neoformans cells, culture
filtrate antigen, and individual components of the antigen.
Infect Immun 1993; 61: 5067-5077.
26. Collins HL, Bancroft GJ. Encapsulation of Cryptococcus
neoformans impairs antigen-specific T-cell responces.
Infect Immun 1991; 59: 3883-3888.
27. Dong ZM, Murphy JW. Intravascular cryptococcal
culture filtrate (CneF) and its major component
glucuronoxylomannan (GXM) are potent inhibitors of
leukocyte accumulation. Infect Immun 1995; 63: 770-
778.
28. Doering TL, Nosanchuk JD, Roberts WK, Casadevall A.
Melanin as a potential cryptococcal defence against
microbiocidal proteins. Med Mycol 1999; 37: 175-181.
29. Williamson PR, Wakamatsu K, Ito S. Melanin
biosynthesis in Cryptococcus neoformans. J Bacteriol
1998; 180:1570-1572.
30. Jacobson ES, Tinnell SB. Antioxidant function of fungal
melanin. J Bacretiol 1993; 175: 7102-7104.
31. Wang I, Casadeval A. Susceptibility of melanized and
nonmelanized Cryptococcus neoformans to nitrogen- and
oxygen-derived oxidants. Infect Immun 1994; 62: 3004-
3007.
32. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR,
Williamson PR. Effect of the laccase gene CNLACI, on
virulence of Cryptococcus neoformans. J Exp Med 1996;
1: 377-386.
33. Williamson PR. Laccase and melanin in the pathogenesis
of . Front Biosci 1997; 2: 99-107.
34. Wang I, Aisen P, Casadeval A Cryptococcus neoformans
melanin and virulence: mechanism of action. Infect
Immun 1995; 63: 3131-3136.
35. Liu L, Tewari RP, Williamson PR. Laccase protects
Cryptococcus neoformans from antifungal activity of
alveolar macrophages. Infect Immun 1999; 67: 6034-
6039.
36. Jacobson ES, Jenkins ND, Todd JM. Relationship
between superoxide dismutase and melanine in a
pathogenic fungus. Infect Immun 1994; 62: 4085-4086.
37. Aoki S, Ito-Kuwa S, Nakamura K, Kato J, Ninomiya K,
Vidotto V. Extracellular proteolytic activity of
Cryptococcus neoformans. Mycopathologia 1994; 128:
143-150.
38. Leone R, Çabeli P, Sinicco A, Ito-Kuwa S, Aoki S,
Vidotto V. Relationship between protease production and
capsule size in Cryptococcus neoformans. J Med Mycol
1999; 9: 42-44.
39. Vidotto V. Phospholipase activity in Cryptococcus
neoformans. Mycopathologia 1996; 136: 119-123.
40. Chen SCA, Muller M, Zhou JZ, Wright LC, Sorrell TC.
Phospholipase activity in Cryptococcus neoformans: a
new virulence factor? J Infect Dis 1997; 175: 414-420.
41. Chen SCA, Wright LC, Santangelo RT, Muller M, Moran
VR, Kuchel PV, Sorrell TC. Identification of
extracellular phospholipase B, lysophospholipase, and
acyltransferase produced by Cryptococcus neoformans.
Infect Immun 1997; 65: 405-411.
42. Vidotto V, Leone R, Sinicco A, Ito-Kuwa S, Criseo G.
Comparison of phospholipase production in
Cryptococcus neoformans isolates from AIDS patients
and bird droppings. Mycopathologia 1998; 142: 71-76.
43. Pienthaweechai K, Ito-Kuwa S, Nakanura K, Aoki S,
Vidotto V, Koga-Ito CY, Sinicco A. Phospholipase
production in Cryptococcus neoformans isolates from
AIDS patients in Thailand and Italy. J Mycol Med 1998;
8: 00-000.
44. Goldman DL, Fries BC, Franzot SP, Montella L,
Casadevall A. Phenothypic switching in the human
pathogenic fungus Cryptococcus neoformans is
associated with changes in virulence and pulmonary
inflammatory response in rodents. Proc Natl Sci USA
1998; 95: 14967-14972.
Thank you for copying data from http://www.arastirmax.com
